

Right-Sided Lesions/Interval Cancers and Surveillance after Colorectal Neoplasia

WEO CRC SC Expert Working Groups – Joint Session

Thursday, April 22, 2021 – 6.00 pm (CEST, Berlin, Amsterdam)

Corresponding Pacific Time: 9.00 am

Corresponding Eastern Time: 12.00 pm/Noon

Chairs: Matthew Rutter, Jeffrey Lee (Right-Sided-Lesions/Interval Cancers)
Rodrigo Jover, Uri Ladabaum (Surveillance after Colorectal Neoplasia)

Session Title: Reducing post-colonoscopy disease burden – updates on PCCRC and post-polypectomy surveillance.

Webinar via Zoom Webinars, registered participants will receive link for meeting.

Webinar Program (CEST)

6.00 pm	Welcome by Expert Working Group Co-Chairs	<i>Matthew Rutter (UK) and Jeffrey Lee (USA)</i>
6.05 pm	Is there a role of an interval FIT for the prevention of PCCRC? incl. discussion	<i>Han-Mo Chiu (Taiwan)</i>
6.20 pm	Are PCCRCs more lethal compared to detected CRCs? The view from Sweden The view from Canada	<i>Anna Forsberg (Sweden) Fahima Dossa (Canada)</i>
6.40 pm	Discussion	
6.55 pm	Break (5 minutes)	
7.00 pm	Welcome by Expert Working Group Co-Chairs	<i>Rodrigo Jover (Spain), Uri Ladabaum (USA)</i>
7.05 pm	Systematic review and meta-analysis on surveillance after excision of high-risk adenomas. Incl. discussion	<i>Sandra Baile-Maxia (Spain)</i>
7.25 pm	Are we successfully reducing CRC risk in patients with baseline High Risk Adenomas? Review and active discussion: 1) What does the elevated future CRC risk <u>despite HRA removal</u> mean in patients with baseline HRA?	<i>Uri Ladabaum (USA)</i>

- 2) Can we do better at baseline colonoscopy?
Implications for surveillance?
- 3) How much of surveillance in these patients is
aimed at early CRC detection vs. CRC
prevention?
- 4) Research ideas / proposals? What datasets /
populations / resources are available?

8.00 pm Meeting adjourns

We would like to thank the following partners for their support:

 **alfresa**

Alfresa Pharma Corporation

 **EIKEN CHEMICAL**

 **Polymedco, Inc.**

SENTINEL
D I A G N O S T I C S